clinical features of TB-IRIS in HIV/MTB co-infected patients and latently infected patients remain unclear. How to confirm early diagnosis with TB-IRIS is still a challenging issue.
In present study, HIV newly infected patients were recruited from March 2012, and the patients were divided into three groups, namely HIV/TB co-infection, HIV/MTB latent infection, and HIV infection groups, according to the inclusion criteria. Treatments were applied according to the protocol, and patients were followed up to investigate the incidence and clinical features of TB-IRIS in the three groups.
Herein, we have reported our observations to help clinicians in the early diagnosis and treatment of TB-IRIS in HIV/TB co-infected patients.
PATIENTS AND METHODS

Clinical characteristics
Newly infected patients with HIV were treated at the Third People's Hospital of Shenzhen, China between March 2012 and March 2013, and were recruited to the study. The inclusion criteria were developed according to the Guideline for HIV/AIDS Diagnosis and Treatment (2011 edition) 2 and issued by the
Group of AIDS, Society of Infectious Diseases,
Chinese Medical Association, were as follows: 1) Age ≥18 years; 2) CD4 + T cell count lower than 350 cells/μl as determined within 30 days prior to recruitment; 3) Absence of chronic diseases of the heart, brain, lung, liver and kidney; 4) Absence of other AIDS-related opportunistic infections (confirmed by laboratory examinations; 5) No previous treatment with antiretroviral therapy, and 6) Provision of informed consent. Finally 159 eligible patients were included in present study. TB-IRIS diagnostic criteria: French et al have laid down criteria so as to aid the diagnosis. 3 Major criteria: Atypical presentation of "opportunistic infections (OI) or tumors" in patients responding to antiretroviral therapy. Decrease in plasma HIV RNA level by at least 1 log 10 copies/ml. Minor criteria: (1) Increased blood CD4 + T-cell count after HAART; (2) Increase in immune response specific to the relevant pathogen, e.g. DTH response to mycobacterial antigens; (3) Spontaneous resolution of disease without specific antimicrobial therapy or tumor chemotherapy with continuation of antiretroviral therapy.
According to the Guideline for Pulmonary Tuberculosis Diagnosis and Treatment, 4 issued by the Tuberculosis Society, Chinese Medical Association, 55 patients presented with HIV/TB co-infection (which were referred to as the co-infection group), and none were treated with anti-TB therapy. Three patients with non-TB mycobacterial infection were excluded, 2 patients were lost to follow-up, and thus we finally had 50 patients in the co-infection group who were available for complete follow-up. According to ELISpot assays, 52 patients displayed HIV/MTB latent infections (latent infection group). However, 2 patients were lost to followup, and thus finally 50 patients in latent infection group were available for following-up. Additionally, 52 patients were infected with HIV(HIV infection group), and 2 of them were lost to follow-up. Thus, we finally got 50 patients available for following-up. The anti-TB therapy applied in present study was the HRZE strategy, which is essentially a combination of Isoniazid, Rifampicin, Ethambutol and Pyrazinamide. HAART therapy was performed for patients after a 2-week course of HRZE treatment. 5 The preferred treatment strategy of HAART was a combination of Zidovudine (AZT), Epivir (3TC) and Efavirenz (EFV). The secondary treatment strategy of HARRT was a combination of TEF, 3TC and EFV.
Ethics approval
This study was conducted according to the Declaration of Helsinki. All the related documents (including approval documents, study protocol, informed consent forms and guidelines for investigators) were presented to the ethics committee in each research center for approval. Following-up studies were carried out for patients in all 3 groups, and blood samples were collected before and at 6 time points after HAART treatment (namely before the treatment and at 0.5-, 1-, 2-, 3-, 6-, and 12-month after treatment). Other parameters including leukocyte counts (WBC), hemoglobin (Hb), platelets (PLT), lymphocytes (Lym), alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin (ALB), globulin (GLO), total bilirubin (TB), serum creatinine (Cr), total CD4 + cell counts, and HIV-RNA load were also detected. Levels of HIV-RNA were described as an logarithm.
Detection of indexes
Statistical analysis SPSS 13.0 software was applied for the statistical analysis. Chi-square test was used for the comparison of demographic characteristics, clinical symptoms, experimental results, and incidence of TB-IRIS among the 3 groups. An alpha value of P ≤ 0.05 was considered statistically significant.
RESULTS
Clinical characteristics of patients before HAART treatment
The duration of TB disease in all 50 patients in the coinfection group ranged from 2 weeks to 2 months, and the mean time was 5.82 ± 3.35 weeks. In addition, 90% patients in co-infection group were male, 40% with a history of smoking, but none of them copresented with a history of diabetes. Additionally, 18% patients were with other basic diseases, although the differences among the 3 groups were not statistically significant. In addition, no statistically significant differences in WBC counts, liver function, renal function, LDH, ESR, CRP, CD4 + cell counts, and HIV RNA was found among the 3 groups (Table 1) .
TB-IRIS in co-infection and latent infection groups TB-IRIS was found in 20 (40%) patients in co-
infection group, and induced deaths were found in 2 (10%) patients. The period between HAART treatment and TB-IRIS diagnosis ranged from 1 week to 3 months. In terms of specificity, 65% patients were diagnosed 2 weeks after HAART treatment, while 2 cases were diagnosed at 10 and 12 weeks after HAART treatment, respectively. The ages of patients at TB-IRIS diagnosis ranged from 10 to 39 years old. By contrast, only 1 patient in latent group developed TB-IRIS, and no patient in HIV infection group developed TB-IRIS. The characteristics of patients who developed TB-IRIS are displayed in Table 2 .
Clinical features of patients in co-infection group that developed TB-IRIS
For patients in co-infection group, all 20 (100%) patients developing TB-IRIS presented with the clinical symptom of repeated fever, while only 2 of the other 30 patients (6.7%) who did not develop TB-IRIS presented with repeated fever. Chi-square test showed that the differences were statistically significant (χ 2 = 42.424, P < 0.001). In addition, 18
patients were with a temperature higher than 39℃ when TB-IRIS were confirmed, with the incidence rate as 90.0% (18/20). By contrast, the incidence of fever with a temperature higher than 39 ℃ was only 3.3% (1/30) in patients developing TB-IRIS in co-infection group. The difference was statistically significant (χ 2 = 38.257, P < 0.001). No significant difference was found in other symptoms, including chills, weakness, mental state, appetite, shortness of breath, diarrhea, cough, and expectoration between patients who developed and those who did not develop TB-IRIS in co-infection group (P > 0.05, Table 3 ).
Laboratory features of patients in co-infection group who developed TB-IRIS
For patients in co-infection group, CD4 + cell counts increased 4-fold higher in all (20/20, 100%) patients that developed TB-IRIS, and HIV RNA levels decreased by 2 logarithms in 95% (19/20) patients, with statistically significant difference compared with the patients who did not develop TB-IRIS in co-infection group (P < 0.001). The inflammatory Table 2 . were significantly different between patients who developed and those who did not develop TB-IRIS in co-infection group. By contrast, no statistically significant differences in WBC, ALT, AST, Cr and GLO were found between patients who developed and those who did not develop TB-IRIS in co-infection group (Table 3) .
Characteristics of patients in co-infection and latent infection groups with TB-IRIS diagnosis
DISCUSSION
Approximately one quarter to one third of patients with AIDS may develop IRIS after HAART, and mycobacterium TB is the most common IRIS-related pathogen. The incidence rate of TB-IRIS in patients co-infected with HIV, and TB ranges from 11% to 68.8%. 6, 7 The co-infection rate of HIV and TB is increasing steadily in China, which makes TB-IRIS the most important and commonly early complication for patients who received HAART treatment, and coinfected with HIV and TB. However, only several studies have reported the incidence of TB-IRIS and the clinical features.
In this prospective study, we found that 20 of 50 patients with HIV/TB co-infection developed TB-IRIS, with an incidence rate of 40%. Two of these 20 patients died, with a mortality rate of 10%. By contrast, only 1 of the 50 patients with HIV/MTB latent infection developed TB-IRIS, with an incidence rate of 2%, no death was identified in this group. In a previous study performed by Huruy et al, 7 the incidence rate of TB-IRIS was as high as 68.8% in AIDS patients who were treated with HAART in Ethiopia. Another retrospective study conducted in Guangxi Province, China also demonstrated that the incidence rate of IRIS in HIV/TB co-infected patients was about 48.8%. 8 These results suggested that TB-IRIS is a critical challenge for patients with HIV/TB co-infection. Studies have shown that TB-IRIS occurs in African patients at the 5th day of HAART, while for most patients, the symptoms appeared at about 2-6 weeks after HAART. For some cases, the symptoms were evident even 1-4 years after HAART. 7 In present study, the earliest time to TB-IRIS was 7 days after HAART treatment in HIV/TB co-infected group, while the last patient displaying symptoms occured 5 (25) 11 (55) 1 (5.0) 15 (75) 20 (100) 2 (10) 19 (95) 2 ( longer than 90 days after HAART. Additionally, 65% (13/60) patients occurred TB-IRIS at 7-to 14-day after HAART. It is also found that TB-IRIS occurred longer than 2 months after HAART in the 2 observed deaths. This observation was consistent with the results of van Oosterhout et al. 9 The ages of patients with TB-IRIS diagnosis were 20-39 years old, and the 2 patients who died with TB-IRIS diagnosis were 28 years and 38 years, respectively. It is suggested that young patients are at a high risk of developing TB-IRIS, which suggested that TB-IRIS is associated with the patient's age and the duration of HAART treatment. [12] [13] [14] However, further studies are warranted to explore the exact mechanism. The main symptoms of patients presenting with TB-IRIS was repeated fever (20/20, 100%) in present study, and the incidence was significantly different as compared with co-infected patients who did not develop TB-IRIS (χ 2 = 42.4, P < 0.01). However, no significant difference was found between the patients who develop and those who did not develop TB-IRIS in co-infection group when considering other symptoms like chills, weakness, mental state, appetite, shortness of breath, diarrhea, cough and expectoration (P > 0.05). These findings suggested that the symptoms of TB-IRIS could be different from those induced simply by TB infection, and the systemic toxic symptoms were relatively mild when fever appeared in patients with TB-IRIS. This might assist clinicians in early identification of the causes of fever in HIV/TB coinfected patients by reviewing their medical history. I n p r e s e n t s t u d y, c l i n i c a l l a b o r a t o r i a l examinations revealed that the levels of CRP (75%, 15/20), ESR (60%, 12/20), and LDH (55%, 11/20) increased significantly in patients with TB-IRIS as compared to those who without TB-IRIS (P < 0.01). This suggested that TB-IRIS is associated with increased levels of CRP, ESR and LDH. Previous studies have demonstrated that CD4 + cells increased after HARRT. Additionally, the decrease in number of HIV RNA is associated with short time duration between the disease onset and the initiation of ART treatment. Moreover, high level of CRP was a risk factor of IRIS. 15 These results were inconsistent with our findings. Therefore, if increased levels of CRP, ESR and LDH are found in HIV/TB co-infected patients, some features including the duration of HAART treatment, clinical symptoms, CD4 + cell counts and HIV RNA loads should be considered along with the infection to comprehensively evaluate the possibility of developing IRIS and to help make the most appropriate early treatment strategy.
